Cythemias
Conference Coverage
MF assessment and treatment an ‘evolution’ from the past
NEW YORK—The 11th NCCN Congress: Hematologic Malignancies coincided with the release of the inaugural edition of the NCCN treatment guideline on...
News
NCCN releases guidelines for managing MF
The National Comprehensive Cancer Network (NCCN) has published new clinical practice guidelines for myeloproliferative neoplasms (MPNs). The...
News
Teva launches generic imatinib tablets in US
Photo by Steven Harbour Teva Pharmaceutical Industries Ltd.
News
Products granted orphan designation for use in HSCT
BPX-501 consists of genetically modified donor T cells incorporating the CaspaCIDe safety switch, which is designed to eliminate the T cells in...
News
Blood disorders prove costly for European economy
chemotherapy Photo by Rhoda Baer Malignant and non-malignant blood disorders cost 31 European countries a total of €23 billion in 2012, according...
News
Immunotherapy may benefit relapsed HSCT recipients
Photo from Business Wire Results of a phase 1 study suggest that repeated doses of the immunotherapy drug ipilimumab is a feasible treatment...
News
Inhibitor produces responses in advanced SM
Results of a phase 2 trial suggest the multikinase inhibitor midostaurin can repair organ damage in patients with advanced systemic mastocytosis (...
News
One-size-fits-all approach no good for low-risk ET
Photo by Sage Ross Results of a retrospective study suggest that patients with low-risk essential thrombocythemia (ET) may benefit from a...
News
Peptides show promise for treating thalassemia, PV
Preclinical research suggests synthetic peptides called minihepcidins could potentially treat beta-thalassemia and polycythemia vera (PV)....
News
Tools may aid transition from pediatric to adult care
Photo courtesy of the CDC WASHINGTON, DC—The American Society of Hematology (ASH) has created a toolkit to help hematologists aid patients who...
News
Health Canada approves ruxolitinib for PV
Image courtesy of AFIP Health Canada has approved the JAK1/2 inhibitor ruxolitinib (Jakavi) for the control of hematocrit in adult patients with...